{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:25:02Z","timestamp":1788222302252,"version":"build-2803163510"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,3,15]]},"DOI":"10.2169\/internalmedicine.9613-22","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T22:12:02Z","timestamp":1660083122000},"page":"929-933","source":"Crossref","is-referenced-by-count":6,"title":["Severe Lupus Myocarditis Preceded by Mesalazine-induced Lupus"],"prefix":"10.2169","volume":"62","author":[{"given":"Mai","family":"Yamashita","sequence":"first","affiliation":[{"name":"Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iku","family":"Shirasugi","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Ichise","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Ueda","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Saegusa","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Katsanos K, Voulgari P, Tsianos E. Inflammatory bowel disease and lupus: a systematic review of the literature. J Crohns Colitis 6: 735-742, 2012.","DOI":"10.1016\/j.crohns.2012.03.005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Vaglio A, Grayson P, Fenaroli P, et al. Drug-induced lupus: traditional and new concepts. Autoimmun Rev 17: 912-918, 2018.","DOI":"10.1016\/j.autrev.2018.03.016"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Pretel M, Marques L, Espana A. Drug-induced lupus erythematosus. Actas Dermo-Sifiliograficas 105: 18-30, 2014.","DOI":"10.1016\/j.ad.2012.09.007"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Perez-Alamino R, Maldonado-Ficco H, Maldonado-Cocco J. Rheumatic manifestations in inflammatory bowel diseases: a link between GI and rheumatology. Clin Rheumatol 35: 291-296, 2016.","DOI":"10.1007\/s10067-015-3116-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78: 1151-1159, 2019.","DOI":"10.1136\/annrheumdis-2020-218615"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tan E, Cohen A, Fries J, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277, 1982.","DOI":"10.1002\/art.1780251101"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725, 1997.","DOI":"10.1002\/art.1780400928"},{"key":"8","unstructured":"8. Petri M, Orbai A, Alarc\u00f3n G, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64: 2677-2686, 2012."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Naramala S, Konala V, Adapa S, et al. Recurrent inflammatory myositis as an extra-intestinal manifestations of dormant ulcerative colitis in a patient on long-term mesalamine. Case Rep Gastrointest Med 7: 2090379, 2019.","DOI":"10.1155\/2019\/2090379"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pollack A, Kontorovich A, Fuster V, Dec G. Viral myocarditis-diagnosis, treatment options, and current controversies. Nat Rev Cardio 12: 670-680, 2015.","DOI":"10.1038\/nrcardio.2015.108"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gunnarsson I, Forslid J, Ringertz B. Mesalazine-induced lupus syndrome. Lupus 8: 486-488, 1999.","DOI":"10.1177\/096120339900800616"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kirkpatrick AW, Bookman AA, Habal F. Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease. Can J Gastroenterol 13: 159-162, 1999.","DOI":"10.1155\/1999\/361431"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Dent MT, Ganapathy S, Holdsworth CD, Channer KC. Mesalazine induced lupus-like syndrome. BMJ 305: 159, 1992.","DOI":"10.1136\/bmj.305.6846.159-b"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 36: 1089-1094, 1997.","DOI":"10.1093\/rheumatology\/36.10.1089"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Ara\u00fajo-Fern\u00e1ndez S, Ahij\u00f3n-Lana M, Isenberg DA. Drug-induced lupus: including anti-tumour necrosis factor and interferon induced. Lupus 23: 545-553, 2014.","DOI":"10.1177\/0961203314523871"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Beaudoin S, Gonzalez A. Evaluation of the patient with pleural effusion. CMAJ 190: E291-E295, 2018.","DOI":"10.1503\/cmaj.170420"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mai Y, Ujie H, Nishimura M, et al. Chemiluminescent enzyme immunoassay failed to detect anti-desmoglein 3 antibodies in a case of pemphigus vulgaris. J Dermatol 44: E242-E243, 2017.","DOI":"10.1111\/1346-8138.13932"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mummert E, Fritzler M, Sj\u00f6wall C, Bentow C, Mahler M. The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. J Immunol Methods 459: 11-19, 2018.","DOI":"10.1016\/j.jim.2018.05.014"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/6\/62_9613-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T03:23:01Z","timestamp":1679109781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/6\/62_9613-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9613-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"article-number":"9613-22"}}